Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

INTRODUCTION: Response to trastuzumab in metastatic breast cancer correlates with expression of the high binding variant (158V) of the activating Fcγ receptor IIIA (CD16A). We engineered MGAH22, a chimeric anti-HER2 monoclonal antibody with specificity and affinity similar to trastuzumab, with an Fc...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordstrom, Jeffrey L, Gorlatov, Sergey, Zhang, Wenjun, Yang, Yinhua, Huang, Ling, Burke, Steve, Li, Hua, Ciccarone, Valentina, Zhang, Tengfei, Stavenhagen, Jeffrey, Koenig, Scott, Stewart, Stanford J, Moore, Paul A, Johnson, Syd, Bonvini, Ezio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326565/
https://www.ncbi.nlm.nih.gov/pubmed/22129105
http://dx.doi.org/10.1186/bcr3069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326565/
https://www.ncbi.nlm.nih.gov/pubmed/22129105
http://dx.doi.org/10.1186/bcr3069

Ejemplares similares